CurtisEB, KrechR, WalshTD.: Common symptoms in patients with advanced cancerJ Palliat Care1991; 7(2): 25–29.
2.
WachtelT, Allen-MastersonS, ReubenD, GoldbergR, MorV.: The end stage cancer patient: terminal common pathwayHospice Journal1988; 4(4): 43–80.
3.
KleinS, SimesJ, BlackburnG.: Total parenteral nutrition and cancer clinical trialsCancer1986; 58: 1378–1386.
4.
American College of Physicians. Parenteral nutrition in patients receiving cancer chemotherapy.Ann Int Med1989; 110: 734–736.
5.
LowrySF, MoldawerLL.: Tumor necrosis factor and other cytokines in the pathogenesis of cancer cachexiaPrinciples and Practice of Oncology Updates1990 (August); 4(8): 1–12.
6.
LevineB, KalmanJ.MayerL, FillitHM, PackerM.: Elevated circulating levels of tumor necrosis factor in severe chronic heart failureN Engl J Med1990; 323: 236–241.
7.
SherryBA, GelinJ, FongY, MaranoM, WeiH, CeramiA, LowryS, LundholmKG, MoldawerLL.: Anticachectin/tumor necrosis factor-a antibodies attenuate development of cachexia in tumor modelsFASEB J1989; 3: 1956–1962.
8.
BrueraE, ChadwickS, FoxR, HansonJ, MacDonaldN.: Study of cardiovascular autonomic insufficiency in advanced cancer patientsCancer Treatment Reports1986; 70: 1383–1387.
9.
BrueraE (ed).: Palliative Care Rounds: Autonomic failure in patients with advanced cancerJ Pain Sympt Manag1989; 4(3): 163–167.
10.
NelsonKA, WalshTD, SheehanFG, O'DonovanPB.: Assessment of upper gastrointestinal motility in the cancer-associated dyspepsia syndromeJ Palliat Care1993; 9(1): 27–31.
11.
NelsonKA, WalshTD.: Metoclopramide in anorexia caused by cancer-associated dyspepsia syndrome (CADS)J Palliat Care1993; 9(2): 14–18.
12.
BrownCK, KhanderiaU.: Use of metoclopramide, domperidone, and cisapride in the management of diabetic gastroparesisClin Pharmacol1990; 9: 357–365.
13.
LoprinziCL, GoldbergRM, BurnhamNL.: Cancer-associated anorexia and cachexiaImplications for drug therapy. Drugs1992; 43(4): 499–506.
14.
EttingerAB, PortenoyRK.: The use of corticosteroids in the treatment of symptoms associated with cancerJ Pain Sympt Manag1988; 3: 99–103.
15.
DellaCunaGR, PellegriniA, PiazziM.: Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: A placebo-controlled, multi-center studyEuro J Cancer Clin Oncol1989; 25: 1817–1821.
16.
PopielaT, LucchiR, GiongoF.: Methylprednisolone as palliative therapy for female terminal cancer patientsEuro J Cancer Clin Oncol1989; 25: 1823–1829.
17.
TwycrossR.: Corticosteroids in advanced cancerBr Med J1992; 305: 969–970.
18.
WalshD, AvashiaJ.: Glucocorticoids in clinical oncologyCleveland J Med1992; 59: 505–515.
19.
BrueraE, RocaE, CedaroL, CarrraroS, ChaconR.: Action of oral methylprednisolone in terminal cancer patients: A prospective double-blind studyCancer Treatment Reports1985; 69: 751–755.
20.
FarrWC.: The use of corticosteroids for symptom management in terminally ill patientsAm J Hospice Care1990; 7(1)(January/February): 41–46.
21.
TannockI, GospodarowiczM, MeakinW, PanzarellaT, StewardL, RiderW.: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of responseJ Clin Oncol1989; 7: 590–597.
22.
NeedhamPR, DaleyAF, LennardRF.: Steroids in advanced cancer: Survey of current practiceBr Med J1992; 305: 999.
23.
LoprinziCL, EllisonNM, GoldbergRM, MichalakJC, BurchPA.: Alleviation of cancer anorexia and cachexia: Studies of the Mayo Clinic and the North Central Cancer Treatment GroupSeminars Oncology1990; 17(6)(Suppl. 9): 8–12.
24.
LoprinziCL, EllisonNM, SchaidDJ, KrookJE, AthmannLM, DoseAM, MailliardJA, JohnsonPS, EbbertLP, GeeraertsLH.: Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexiaJ Nat Cancer Inst1990; 82(13): 1127–1132.
25.
TchekmedyianNS, HickmanM, SiauJ, GrecoA, AisnerJ.: Treatment of cancer anorexia with megestrol acetate: Impact on quality of lifeOncol1990; 4(5)(May): 185–192.
26.
TchekmedyianNS, HickmanM, SiauJ.: GrecoFA, KellerJ, BrowderH, AisnerJMegestrol acetate in cancer anorexia and weight loss.Cancer1992; 69: 1268–1274.
27.
BrueraE, MacmillanK, KuehnN, HansonJ, MacDonaldRN.: A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancerCancer1990; 66: 1279–1282.
28.
VonRoennJH, MurphyRL, WeberKM, et al.: Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infectionAnn Int Med1988; 109: 840–841.
29.
LelliG, AngelelliB, GiambiasiME, ColalongoF, CamaggiCM, CostantiB, StrocchiE, PannutiF.: The anabolic effect of high dose medroxyprogesterone acetate in oncologyPharmacological Research Communications1983; 15(6): 561–568.
30.
LoprinziCL, SchaidDJ, BurnhamNL, JensenMD.: Body-composition changes in patients who gain weight while receiving megestrol acetateJ Clin Oncol1993; 11: 152–154.
31.
TchekmedyianNS, TaitN, MoodyM.: Aisner J High dose megestrol acetate: A possible treatment for cachexia.JAMA1987; 257: 1195–1198.
32.
MussHB, CaseLD, CapizziRL, CooperMR, CruzJ, JacksonD, RichardsF, PowellBL, SpurrCL, WhiteD, et al.: High- versus standard-dose megestrol acetate in women with advanced breast cancer: A Phase II trial of the Piedmont Oncology AssociationJ Clin Oncol1990; 8(11): 1797–1805.
33.
HenryK, RathgaberS, SullivanC, McCabeK.: Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexiaAnn Int Med1992; 116: 53–54.
34.
KardinalCG, LoprinziCL, SchaidDJ, HaasAC, DoseAM, AthmannLM, MailliardJA, McCormackGW, GerstnerJB, ScharayMF.: A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexiaCancer1990; 65: 2657–2662.
35.
ChlebowskiRT, BulcavageL, GrosvenorM, OktayE, BlockJB, ChlebowskiJS, AliI, ElashoffR.: Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancerJ Clin Oncol1990; 8: 9–15.
36.
SmigelK.: Hydrazine sulfate used in cancer patientsJ Nat Cancer Inst1990; 82(4): 254.
37.
TorosianMH, DonowayRB.: Total parenteral nutrition and tumor metastasisSurgery1991; 109: 597–601.
